Pioglitazona [Inn-Spanish] en es it fr

Pioglitazona [Inn-Spanish] Brand names, Pioglitazona [Inn-Spanish] Analogs

Pioglitazona [Inn-Spanish] Brand Names Mixture

  • No information avaliable

Pioglitazona [Inn-Spanish] Chemical_Formula


Pioglitazona [Inn-Spanish] RX_link


Pioglitazona [Inn-Spanish] fda sheet

Pioglitazona_[Inn-Spanish] FDA

Pioglitazona [Inn-Spanish] msds (material safety sheet)

Pioglitazona_[Inn-Spanish] MSDS

Pioglitazona [Inn-Spanish] Synthesis Reference

K. Meguro, T. Fujita, U.S. Pat. 4,687,777 (1987)

Pioglitazona [Inn-Spanish] Molecular Weight

356.44 g/mol

Pioglitazona [Inn-Spanish] Melting Point


Pioglitazona [Inn-Spanish] H2O Solubility


Pioglitazona [Inn-Spanish] State


Pioglitazona [Inn-Spanish] LogP

No information avaliable

Pioglitazona [Inn-Spanish] Dosage Forms

Oral tablets

Pioglitazona [Inn-Spanish] Indication

Treatment of Type II diabetes mellitus

Pioglitazona [Inn-Spanish] Pharmacology

Pioglitazone, a member of the drug group known as the thiazolidinediones or "insulin sensitizers", is not chemically or functionally related to the alpha-glucosidase inhibitors, the biguanides, or the sulfonylureas. Pioglitazone targets insulin resistance and, hence, is used alone or in combination with insulin, metformin, or asulfonylurea as an antidiabetic agent.

Pioglitazona [Inn-Spanish] Absorption

Following oral administration, in the fasting state, pioglitazone is first measurable in serum within 30 minutes, with peak concentrations observed within 2 hours. Food slightly delays the time to peak serum concentration to 3 to 4 hours, but does not alter the extent of absorption.

Pioglitazona [Inn-Spanish] side effects and Toxicity

Hypogycemia; LD50=mg/kg (orally in rat)

Pioglitazona [Inn-Spanish] Patient Information

Pioglitazona [Inn-Spanish] Organisms Affected

Humans and other mammals